Literature DB >> 6204097

Abnormal expression of vimentin intermediate filaments in human lymphoid cell lines with deletion or translocation of the distal end of chromosome 8.

K Dellagi, J C Brouet, M M Portier, G M Lenoir.   

Abstract

The expression of vimentin, the major polypeptide of the intermediate filament (IFM) cytoskeleton of lymphoid cells, was studied in normal and malignant human lymphoid cell lines. Cells from 24 of 27 Burkitt's lymphoma cell lines (BLCL) were found to have an absent (16 lines) or decreased (8 lines) expression of vimentin IFM. In contrast, non-Burkitt's malignant lymphoid cell lines (5 lines) and lymphoblastoid cell lines (LCL) derived from normal B-cells (45 lines) exhibited a well-developed vimentin IFM network. However, low expression of vimentin was also found in 3 LCL derived from patients with the Langer-Giedion syndrome, which is characterized by a deletion of the distal end of chromosome 8. Treatment of vimentin-negative BLCL and Langer-Giedion LCL with azacytidine led to a transient reexpression of vimentin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6204097

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  4 in total

1.  An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes.

Authors:  D Liebowitz; R Kopan; E Fuchs; J Sample; E Kieff
Journal:  Mol Cell Biol       Date:  1987-07       Impact factor: 4.272

2.  Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin's lymphomas.

Authors:  C Gustmann; M Altmannsberger; M Osborn; H Griesser; A C Feller
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

3.  A human T lymphoblastic cell line lacks lamins A and C.

Authors:  M N Guilly; A Bensussan; J F Bourge; M Bornens; J C Courvalin
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

4.  Vimentin gene: expression in human lymphocytes and in Burkitt's lymphoma cells.

Authors:  A Lilienbaum; V Legagneux; M M Portier; K Dellagi; D Paulin
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.